Control group:bevacizumab

2 trials

Sponsors

Fudan University Huashan Hospital, The Second Affiliated Hospital of Kunming Medical University

Conditions

Recurrent glioblastomarecurrent glioblastoma

Phase 1

Clinical study of lercanidipine combined with bevacizumab in the treatment of recurrent glioblastoma

Active, not recruitingChiCTR2200059596

The Second Affiliated Hospital of Kunming Medical Universityrecurrent glioblastoma

Start: 2022-05-01Updated: 2024-03-18

Phase 2

Efficacy and safety of hypofractionated re-radiation therapy plus bevacizumab versus bevacizumab alone in the treatment of recurrent glioblastoma: a prospective, single-center, phase II, parallel, randomized, controlled trial

Active, not recruitingChiCTR2000035881

Fudan University Huashan HospitalRecurrent glioblastoma

Start: 2021-01-01Updated: 2020-08-24